Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.87−0.19 (-2.36%)
Close on Nov 13, 2026Market cap $8.23MP/E –Yield –
Moleculin Biotech ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Moleculin Biotech's ebitda for the twelve months ending Sep 30, 2026 was -$29.55M. For fiscal 2025 it was -$25.01M. The highest annual figure on record is -$3.88M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.01M | – |
| FY2024 | Dec 31, 2024 | -$26.52M | – |
| FY2023 | Dec 31, 2023 | -$29.50M | – |
| FY2022 | Dec 31, 2022 | -$30.51M | – |
| FY2021 | Dec 31, 2021 | -$22.80M | – |
| FY2020 | Dec 31, 2020 | -$19.54M | – |
| FY2019 | Dec 31, 2019 | -$17.33M | – |
| FY2018 | Dec 31, 2018 | -$14.96M | – |
| FY2017 | Dec 31, 2017 | -$8.64M | – |
| FY2016 | Dec 31, 2016 | -$3.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.60M | – |
| Q2 FY2026 | Jun 30, 2026 | -$7.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.04M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.09M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.98M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.58M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.45M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.39M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.42M | – |
See a number that looks wrong?